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Abstract 
 Inhibiting histone deacetylases (HDACs) can suppress tumor cell growth eventually 
leading to their death, making HDACs an important drug target. Therefore, understanding the 
mechanism behind inhibiting HDACs is imperative. To determine the thermodynamic 
parameters for the interaction of a known competitive HDAC inhibitor, suberoylanilide 
hydroxamic acid (SAHA), with zinc(II), the metal ion in the HDAC active site, and cobalt(II), 
isothermal titration calorimetry (ITC) was used. The results showed that SAHA binds to zinc(II) 
more strongly than it does to cobalt(II) as the equilibrium binding constants were 4.3 ± 0.5   102 
M
-1
 and 2.0 ± 0.5   102 M-1 for zinc (II) and cobalt (II), respectively. In addition, the calculated 
value of ΔG° for SAHA and zinc(II) of -15.0 ± 0.3 kJ/mol compared to -35.6 kJ/mol for SAHA 
and HDAC suggest that the hydroxamic acid functional group contributes significantly to the 
overall binding energetics of the interaction. Additional titration experiments using the literature 
prototype for hydroxamic acid binding, acetohydroxamic acid (AHA), suggested that the binding 
parameters obtained for SAHA interacting with zinc(II) and cobalt(II) in the non-physiological 
mixture are likely comparable to what they would be in aqueous conditions. To further 
characterize HDAC as a drug target, various nitric oxide (NO) donors, known to chemically 
modify and inhibit HDACs, were screened using an HDAC8 discontinuous fluorogenic assay. 
These assays allowed the effectiveness of the NO donors to be determined through comparison 
of HDAC8 percent activity relative to a control. The screened commercially available NO donors 
displayed no inhibition, whereas SAHA, a different class of NO donor, did decrease HDAC8 
activity. Overall these studies suggest that inhibitors which bind in the active site of HDACs are 
more effective than those that covalently modify cysteine residues.  
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Chapter 1: 
Introduction 
 
1.1 Histone Deacetylases  
 
 Histone deacetylases (HDACs) remove an acetyl group from acetylated side chains of 
lysine residues in histones. The removal of the acetyl group results in positive charge density at 
the N-terminal region of histone proteins, and strengthens their interaction with negatively 
charged DNA, thereby blocking access of transcription factors and down regulating gene 
expression.
1
 Figure 1.1 shows a schematic representation of the action of HDACs. In total, 18 
HDAC isoforms have been discovered in humans and these are divided into four classes based 
on their structural similarity to yeast HDACs, cellular location, tissue specificity and enzymatic 
activity. Class I HDACs (1, 2, 3 and 8) are nuclear proteins that are ubiquitously expressed and 
act as co-repressors for nuclear receptors.
1
 Class II HDACs (4, 5, 6, 7, 9, and 10) can shuttle 
between the nucleus and the cytoplasm in response to cellular signals. This class of HDACs is 
divided into two subclasses, class IIa (HDACs 4, 5, 7, and 9) and IIb (HDACs 6 and 10) where 
class IIb HDACs have two deacetylase domains compared to the single deacetylase domain 
found in class IIa.
 
Class IV is composed of HDAC11 which is found in the nucleus and has a 
similar sequence to class I and II HDACs. Class III HDACs require an NAD
+ 
cofactor
 
for their 
activity while all other classes are Zn
2+
- dependent enzymes.
1 
2 
 
 
Figure 1.1: Action of histone deacetylases and histone acetyltransferases. Histone acetyltransferases catalyze the 
transfer of acetyl groups to lysine residues on the histone protein to allow DNA to unwind and become available for 
transcription. Histone deacetylases catalyze the removal of acetyl groups to keep DNA tightly wound and 
unavailable for transcription. Taken on May 16, 2012 from http://www.di.uq.edu.au/proj6background 
 
 Histones are small, positively charged nuclear proteins that associate with DNA in a 
specific stoichiometry to form a nucleosome. The DNA molecule winds around a core of eight 
histone proteins in a solenoidal supercoil to compact the DNA into a nucleosome. Once formed, 
the nucleosome assembles into chromosomes.
2
 Figure 1.2 shows a generic representation of the 
histones and DNA interacting. This condensed form of DNA plays a major role in gene 
regulation by controlling transcription. Transcription is regulated by protein transcription factors 
that control target genes through interactions with specific regions of the DNA sequence or by 
inducing structural changes to DNA or histone proteins upon binding. Histones have a flexible 
tail in the N-terminal region that sticks out from the surface of the proteins. The tails of histone 
proteins are the main target for many post-translational modifications including acetylation, 
methylation, and phosphorylation.
3 
 Specifically, acetylation of histones is the source of 
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transcriptional activation by hyperacetylation, or transcriptional repression by hypoacetylation. 
The balance between activation and repression is largely controlled by histone acetyltransferases 
(HATs) and HDACs as shown schematically in Figure 1.1.
2
  
 
Figure 1.2: Structure of histone proteins. DNA is wound around the histone proteins to form the condensed form of 
DNA known as chromatin. The action of HDACs is what signals the DNA to remain in the condensed state whereas 
the action of HATs loosens the DNA and makes it available for transcription. Taken on May 16, 2012 from 
http://biology.kenyon.edu/courses/biol114/Chap01/chrom_struct.html 
 
 Most Zn
2+
- dependent HDACs have highly conserved catalytic sites and function as 
multi-protein complexes.
4
 Figure 1.3 shows the crystal structure of HDAC8. It contains a single 
domain, which has eight parallel β-sheets with the C-terminal ends of the β-strands creating large 
loops. Surrounding the β-sheets are eleven α-helices.2  
4 
 
 
Figure 1.3: Crystal Structure of HDAC8 with bound inhibitor. PDB structure 1T69 shows a single domain with 8 
parallel β-sheets surrounded by eleven α- helices.  
Taken on May 30, 2012 from http://www.pdb.org/pdb/explore/explore.do?structureId=1T69 
 
 In the active site, a 12 Å long hydrophobic tunnel leads to the catalytic site containing 
zinc(II). During deacetylation, the tunnel is occupied by the four methylene groups of an 
acetylated lysine residue.  At the bottom of the cavity is the Zn
2+ 
ion, the essential component of 
the catalytic site.
1
 Zinc(II) is penta-coordinated with three sites occupied by Asp178, His180 and 
Asp267; the other two sites are occupied by oxygen atoms, one from the acetyl group from the 
bound substrate and the other from a water molecule as shown in Figure 1.4 A and B.
1
 Recently, 
a cavity has been discovered below the active site.
5
 The cavity is formed from the loops that 
connect the β-strands. The walls of the cavity are mainly composed of glycine and other 
hydrophobic residues. One of the loops separates the cavity from the solvent and probably has 
some flexibility that allows the exchange of cavity contents with the solvent.
4 
While the exact 
function of the cavity is unknown, it is an important consideration in inhibitor design because it 
is suspected to allow enough space for acetylated lysine residues to diffuse into the solvent 
through the cavity to make room for the inhibitor.
 5
 
5 
 
 
 
Figure 1.4: Zinc(II)-dependent HDAC active site components. A. Zinc(II) coordination shell of HDAC8. B. Amino 
acid residues in HDAC8 active site surrounding the catalytic zinc(II). Important hydrogen bond interactions are 
shown with dashed green lines.  Taken on June 1
, 
2011 from  
https://wikis.nyu.edu/display/NYUHPC/Proton-Shuttle+Reaction+Mechanism+for+Histone+Deacetylase+8 
 
A  
B 
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1.2  Modes of Regulation of Histone Deacetylases 
 The ability of HDAC to deacetylate histone proteins that are part of the nucleosome 
requires them to be located in the nuclei of cells. However, class II HDACs are also found in the 
cytoplasm, implying that they can shuttle between the nucleus and cytoplasm of cells.
6
 In the 
cytoplasm, HDACs are unable to make an impact on transcription directly since they are not in 
close proximity to the histone proteins they affect. Because of this, cytoplasmic HDACs are 
unable to deacetylate histones given that their intended substrate is not available.
6
 Thus, the 
proper distribution of HDACs in the nucleus and in the cytoplasm is critical for the correct 
regulation of transcription.
6
 Thus, the sub cellular localization of HDACs is a highly regulated 
pathway that uses a diverse set of mechanisms. 
 The sub cellular location of HDACs can be regulated by the nuclear localization 
sequence (NLS) and the nuclear export signal (NES) which shuttle HDACs through nuclear 
pores.  Additionally, phosphorylation of binding sites on the regulatory protein 14-3-3 dictates 
HDAC localization. Inhibition of HDAC 14-3-3 site phosphorylation results in nuclear 
accumulation of HDACs and transcriptional activation while activation of phosphorylation leads 
to cytoplasmic accumulation and transcriptional inhibition.
6
 There are four broad types of HDAC 
kinases that participate in this regulatory pathway. The first class of kinases shown to regulate 
class IIa HDAC localization is the Ca
2+
/calmodulin-dependant kinase (CaMK) family. This class 
of kinases has been shown to stimulate the disassembly of the HDAC4 complex with myocyte 
enhancer factor 2 (MEF2) leading to cytoplasmic accumulation of HDAC4.
7
  Another type of 
kinase, protein kinase D (PKD), has been shown to directly phosphorylate four serine residues 
leading to nuclear export of HDAC7.
8
 Two members of the microtubule affinity-regulating 
kinase (MARK)/Par-1 family (MARK2 and MARK3) phosphorylate a sequence which is similar 
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to the signaling sites in Class II HDACs.
9
 Finally, the newest HDAC kinase family, AMP-
activated protein kinase/sucrose nonfermenting 1-like kinases (AMPK/SNF1), can use salt-
inducible kinase (SIK1) to phosphorylate two 14-3-3 binding sites of HDAC5.
10
  The existence 
of multiple families of kinases targeting class II HDACs suggests that the biological roles of 
these transcriptional repressors are plentiful.  
 The phosphorylation-dependent regulation of HDACs is a reversible process and thus, 
dephosphorylation via protein phosphatases, specifically PP1 and PP2A, would be expected to 
relocalize HDACs in the nucleus and activate their transcriptional abilities.
6
 This is exemplified 
by calyculin A, which is an inhibitor of PP1 and PP2A. In the presence of this inhibitor, HDAC4 
is located in the cytoplasm of cells which implicates PP1 and PP2A play a critical in the 
mechanism of HDAC4 localization.
11
 Overall, cellular kinases and phosphatases regulate 
different signaling pathways allowing for diverse control of HDAC localization and thereby 
function.  
1.3 Inhibition of HDACs 
 The precise regulation of HDACs in response to different cellular signals is essential for 
proper post-translational modifications of histones. Histone deacetylases are typically over 
expressed in tumor cells and in oncoproteins.
12
 Oncoproteins typically use this increased 
concentration of HDACs to escape the apoptotic pathways and cause cells to proliferate, leading 
to cancer. Thus, inhibiting HDACs can induce a variety of genes leading to multiple mechanisms 
of tumor cell death through apoptosis; this makes them a promising approach for the treatment of 
cancer.
13
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 Many types of HDAC inhibitors (HDACi’s) are available today including short chain 
fatty acids, hydroxamic acids, cyclic tetrapeptides, aliphatic acids and benzamides.  
Suberoylanilide hydroxamic acid (SAHA) and Trichostatin A (TSA) are both hydroxamic acids 
and are the most well studied HDAC inhibitors.
12
 As shown in Figure 1.5, most HDAC inhibitors 
consist of three structural components: a zinc(II) binding group (ZBG) that chelates zinc(II) at 
the active site; a linker region, which in the case of SAHA is six carbons long and sits in the 
hydrophobic tunnel leading to the active site; and a cap which is typically an aromatic moiety 
that interacts with residues on the surface of HDAC enzymes. These structural components are 
responsible for inhibition of HDACs and thus suppression of tumor cell growth.
14
 
 
Figure 1.5: General Structure of HDAC Inhibitor. The general parts that make up an HDAC inhibitor, using the 
structure of SAHA as an example.
1
  
 There are numerous pathways through which class I, II and IV HDACi’s can mediate cell 
death. They can terminate the cell cycle at either G1 or G2/M causing tumor cell death. Histone 
deacetylase inhibitors affect the DNA damage and repair pathway by generating DNA double 
stranded breaks to elicit a DNA damage response leading to apoptosis.
12
 They affect mitosis by 
targeting microtubules and impairing control of mitotic progression. They can induce apoptosis 
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directly through the extrinsic (activation of death receptors and ligands) or intrinsic 
(mitochondrial disruption) pathways. They have an anti-angiogenic effect which stops the 
production of new blood vessels, forcing tumor cells to die.
12
 The inhibitors affect the misfolded 
protein response (MPR) pathway by generating stress to create a response. If the stressor does 
not subside apoptosis will occur. Histone deacetylase inhibitors also induce autophagy in cancer 
cells causing cell death by self digestion of cellular components.
12
 These mechanisms, which 
ultimately lead to apoptosis, are all mediated via HDAC inhibitors.   
1.4 Suberoylanilide Hydroxamic Acid (SAHA) 
 Suberoylanilide hydroxamic acid is currently an FDA approved drug called Vorinostat 
(produced by Merck) that has potency in the nanomolar range and is used for the treatment of 
Cutaneous T-cell lymphoma. It is also in various phases of clinical trials for other types of 
cancers including breast, ovarian, lung, and blood, to name a few.
15
 Suberoylanilide hydroxamic 
acid binds to HDAC and inhibits by inserting its linker into the hydrophobic tunnel and making 
contacts with multiple amino acids. The zinc(II) binding hydroxamic acid group reaches the 
bottom of the tunnel and coordinates to zinc(II) through its carbonyl and hydroxyl oxygen’s to 
create a penta-coordinated ion.
5
 The zinc(II) binding group (ZBG) also hydrogen bonds with 
nearby histidine and tyrosine residues and replaces water in the active site with its hydroxyl 
group. Finally, the aromatic moiety “caps” the opening to the tunnel by interacting with surface 
residues as seen in Figure 1.4, 1.5, and 1.6.
5
 Suberoylanilide hydroxamic acid binds very 
strongly to zinc(II) and the amino acids in the active site with a Kd of 0.58 ± 0.14 µM that was 
determined by a fluorescence assay with coumarin labeled SAHA and HDAC.
16
   
 
10 
 
 
 
Figure 1.6: Skeletal and Crystal structure of SAHA. Interaction of a known HDAC inhibitor, SAHA, with active 
site residues of a HDAC homologue known as HDLP.
4
   
 
1.5 Isothermal Titration Calorimetry 
 Isothermal titration calorimetry (ITC) is an efficient analytical method to determine the 
thermodynamic parameters for a given interaction and can be applied over a broad range of 
systems. Isothermal titration calorimetry works by measuring the heat produced during a titration 
reaction. Upon titration of one reactant (titrant) into the sample cell containing the other reactant 
(titrate), the difference in heat between the thermocoupled reference cell and the sample cell is 
measured. Heat is either released to yield an exothermic reaction or absorbed to yield an 
endothermic reaction.
17
 The heat of reaction is measured through the amount of power required 
11 
 
to maintain a difference in temperature between the reference and sample cells equal to zero. 
With subsequent additions of titrant, the heat signal diminishes, indicating that binding is near 
completion. The concentrations of titrant and titrate are chosen so that only a portion of titrant 
binds upon each titration.
18
 This makes the final binding curve of heat generated per injection 
versus titrant: titrate molar ratio dependent on the affinity of the interaction, stoichiometry, and 
enthalpy change.  
 A c-value defined as the products of stoichiometry (n), equilibrium binding constant (Ka) 
and concentration of titrate, c= (n)(Ka)([cell], is used to determine the appropriate range of 
concentrations to be used in a titration experiment.
18
 An acceptable range of c-values should be 
between 1-1000 or even better, 5-500. This ensures that the resulting binding isotherm has a 
unique shape that allows for the extraction of a one set of binding parameters. Figure 1.7 shows 
an ideal titration curve that has a unique shape. Additionally, it is important to note that to shift 
binding to completion, the titrant concentration is chosen to be at least 10 times the titrate 
concentration.
18
  
 
12 
 
 
Figure 1.7: Ideal shape of a binding isotherm. An S-shaped curve is the ideal shape of a binding isotherm. It is a 
unique curve that only fits one set of parameters.  
 
 
 By integrating the heats of each injection, a binding curve can be constructed. The heat 
generated or absorbed, Q, during the binding interaction is directly related to the fraction of 
ligand bound (Equation 1).
19,19b
 The derivation of the equation for the fraction of ligand bound is 
shown below. After correcting for volume displacement effects, the resulting isotherm is fit 
using an iterative, one set of identical sites model, (Equations 2 and 3) in the Origin 7.0 software 
to determine the thermodynamic parameters.
19b
 Equations 2 and 3 are mathematically equivalent, 
but Equation 3 uses terms that are known, such as total ligand and metal concentration, whereas 
Equation 2 includes the free ligand concentration, which is difficult to calculate. This heat 
represents the change in enthalpy (ΔH) for the interaction. Because the binding is determined via 
titration, the stoichiometry (n) and equilibrium binding constant (Ka) can also be determined.
9,19b
 
Once these parameters have been determined, the actual concentrations of free ligand, free metal 
and the ligand-metal complex can be calculated allowing ΔG to be determined from ΔG° using 
Equation 4.
19a
 From the values of ΔH and ΔG, the Gibb’s free energy equation (Equation 5) can 
13 
 
be used to calculate the value of ΔS.19a However, for our studies, the ΔG° was calculated using 
Equation 6.  
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 In general, for an inhibitor to be an effective drug candidate with minimal toxicity, it 
needs to possess an optimal affinity for the target enzyme but minimal affinity for other proteins 
in the cell. To accomplish this, it is necessary to determine the specific contribution of different 
functional groups of the inhibitor in order to fine tune affinity.  
 To better understand the interaction of SAHA with HDAC and thus its ability as an 
inhibitor, a comprehensive look at the energetic contribution of each of the three regions of 
SAHA was examined. In particular, the contribution of zinc(II) chelation to the overall 
interaction of SAHA with the active site was determined. To do this we examined the binding 
energetics of free zinc(II) to SAHA using isothermal titration calorimetry. The nonpolar nature 
of the major portion of SAHA predicts that it is water insoluble, making it impossible to 
characterize the interaction in a buffer. We therefore turned to a mixture containing 60% 
methanol and 40% N-ethylmorpholine (NEM) buffer at pH 6.80. The binding of zinc(II) to 
acetohydroxamic acid (AHA), which is analog of SAHA without the linker and cap regions, was 
also examined in the methanol:buffer mixture as well as NEM buffer to assess the effect, if any, 
the solvent has on the binding parameters.  
 Studies have suggested that in vitro replacement of zinc(II) in the active site of HDAC 
with cobalt(II) allows the enzyme to retain the highest amount of activity, compared to 
replacement using other transition metals such as iron(II) and nickel(II).
20
 This prompted the use 
of cobalt(II) as the alternative transition metal ion in our ITC studies with SAHA and AHA. 
Cobalt(II) was used to compare the binding parameters obtained, specifically affinity and ΔG°, 
to those obtained from studies of SAHA and AHA binding to zinc(II). The same experiments 
carried out for zinc(II) binding to SAHA and AHA in under both solvent conditions were also 
15 
 
performed using cobalt(II). In all cases, stoichiometry (n), binding affinity (Ka) thus standard 
Gibb’s free energy change (ΔG°), enthalpy change (ΔH) and entropy change (ΔS) were reported. 
 From these studies we wish to gain a greater knowledge of how SAHA interacts with 
different metal ions, specifically zinc(II). Using affinity data, conclusions can be made about 
whether or not metal ion binding is a critical component for binding strength and thus an 
important component of inhibitor design. Studying the binding interaction of SAHA and AHA 
with zinc(II) and cobalt(II) will allow for greater insight into the stoichiometry of binding, the 
strength of binding, and the overall binding energetics of the interaction. These parameters will 
provide previously unavailable data to those studying SAHA for its anti-cancer abilities and 
possible ways to design stronger inhibitors. 
1.6 Nitric Oxide as an Endogenous Signaling Molecule 
 Nitric oxide (NO) is a small, potentially toxic, free radical byproduct of cellular 
metabolism that plays an important role in numerous cellular functions. The most important 
chemical property of NO that facilitates its role as a signaling molecule is that it is neutral, 
allowing it to easily diffuse across cellular membranes. Nitric oxide is produced in vivo from L-
arginine through the action of nitric oxide synthase (NOS).
21
 Nitric oxide synthases have three 
isoforms: neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). 
Neuronal and endothelial NOS are expressed continuously while iNOS is expressed through 
stimulation of various inflammatory agents such as cytokines and endotoxins, thereby inducing 
inflammation.
22
 This inflammation helps kill or slow the growth of invading organisms. 
Inducible NOS is regulated through the availability of calmodulin, L-arginine, NADPH and 
tetrahydrobiopterin. Interestingly, iNOS produces the greatest amount of NO; this ability is 
16 
 
associated with a number of tumor pathologies.
23
 The effectiveness of nitric oxide produced by 
iNOS on tumors seems to be dependent on iNOS activity, distribution, concentration, duration of 
exposure to NO and the cell’s sensitivity to NO. Without the cooperation of existing blood vessel 
networks, which is largely regulated by NO, tumors cannot metastasize.
23
 Not surprisingly, once 
these small inflammatory molecules are produced they play a critical role in the cell signaling 
pathways in the cardiovascular system, in neurons and in the immune system.
21
  
 The mechanisms of NO signaling through covalent modification of amino acid residues 
are plentiful and can be placed into three main categories, including: the S-nitrosylation of thiol 
groups, the formation of peroxynitrite (ONOO
-
) which leads to nitrotyrosine formation, and the 
donation of electrons to transition metal ions, usually copper(II), zinc(II) and iron(II), thereby 
altering the activity of the target enzymes.
24
 Nitrosylation and nitrotyrosine formation occur 
when NO levels are high (>1 µM) whereas electron transfer with transition metals occurs at 
lower concentrations (<1 µM). The pathway that nitric oxide takes to begin a signaling cascade 
depends on the local and surrounding environment concentration of NO. Once synthesized, NO 
diffuses out of the cell and can act locally to affect nearby cells. Its action is restricted to local 
effects because NO is highly unstable. 
24
 
 The ability of nitric oxide to inhibit HDACs is an emerging interest in the medical 
community because of its potential use for the treatment of neoplasia, several types of cancers 
and autoimmune diseases such as rheumatoid arthritis and systematic lupus erythematosus.
25
 
There is increasing evidence that nitric oxide acts by covalently modifying cysteine residues in 
target proteins, such as HDAC8. Cysteine nitrosylation (S-nitrosylation) is a selective and 
specific signal controlled by cellular nitric oxide. S-nitrosylation of transcription factors, such as 
histone deacetylases, is one way that NO can regulate gene expression.
26
 S-nitrosylation 
17 
 
regulates the interaction of transcription factors with chromatin by acetylating or deacetylating 
chromatin that is associated with gene promoter regions. Altering the acetylation state of 
chromatin is accomplished through the action of HATs and HDACs on the gene promoter 
regions of chromatin. Therefore, nitric oxide plays a role in the recruitment of HDACs to the 
proper regions of chromatin that require modifications.  
1.7 Nitric Oxide as an Exogenous Signaling Molecule 
 The use of nitric oxide donors as exogenous signaling molecules was introduced more 
than a century ago through the use of vasodilators. To better understand the involvement of NO 
in a biological system, two approaches can be taken.
27
 The first is to inhibit NO synthases to 
prevent endogenous formation of nitric oxide and the second is to administer exogenous NO. 
The use of exogenous NO is difficult because the delivery of nitric oxide gas is complicated. 
However, to circumvent this problem compounds that release NO in a controlled manner have 
been utilized. These compounds are referred to as “NO-donors”. The action of these exogenous 
NO donors mimics an endogenous NO response to act on a multitude of pathways.
27
  
 Because of their unique properties, the potential uses of nitric oxide donors are broad. 
There are four main types of direct nitric oxide donors: diazeniumdiolates (NONOates), 
heterocyclic NO donors, S-nitrosothiols and S-nitrosylated sugars. Diazeniumdiolates mainly 
release NO through spontaneous chemical decomposition; this process is pH and temperature 
dependent. The most common NONOates are diethylamine (DEA) NONOate and 
diethylenetriamine (DETA) NONOate. The structures of these compounds are shown in Figure 
1.8. The majority of research with these compounds is based in studying cardiac health and 
blood vessel dilation.
28 Another type of diazeniumdiolate is O(2)-(2,4-dinitrophenyl) 1-[(4-
18 
 
ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate or JS-K whose structure is also shown 
in Figure 1.8. This compound is a potent anti-cancer agent, specifically for leukemia that is 
currently in clinical trials. 
29
 
       
Figure 1.8: Structures of Common Diazeniumdiolates. 
 Heterocyclic NO donors differ from other types of NO donors because they require 
cofactors such as molecular oxygen or thiols to facilitate the release of NO.
28
 While little is 
known about this class of compounds they have been shown to acts as vasodilators and to play a 
role in platelet adhesion as well as preventing thrombosis. The most common examples of 
heterocyclic NO donors are molsidomine, SIN-1 and Linsidomine. Figure 1.9 shows the 
structures of these three compounds.   
     
Figure 1.9: Structures of Common Heterocyclic NO donors.  
S-nitrosothiols, another class of NO donors, includes S-nitroso-N-acetylpenacilamine 
(SNAP) and S-nitrosocysteine (L-CysNO). The structures of SNAP and L-CysNO are shown in 
Figure 1.10. This class of compounds is the most advantageous because they do not induce 
19 
 
oxidative stress, are naturally occurring and spontaneously release NO.
28
 These compounds are 
involved in the upkeep of cardiac muscle and inhibition of platelet aggregation.
28
 In cancer, they 
have been shown to modify tumor blood flow and brain permeability of tumors.
30
  
 
        
Figure 1.10: Common S-nitrosothiols. 
The final type of nitric oxide donors are S-nitrosylated sugars. They are a type of thiol 
sugar that generate NO spontaneously. S-nitroslyated sugars are used to treat decreased skin 
blood flow due to decreased vasodilatation.
28
 This group of NO donors is the least studied due to 
problems when the drug is administered orally such as significant and prolonged headaches and 
extreme fatigue.
31
 The most common and widely used version of this class is S-nitroso-1-thio-
2,3,4,6-tetra-O-acetyl-β-D-glucopyranose or D-SNAG whose structure is shown in Figure 1.11.28  
 
 
Figure 1.11: Structure of D-SNAG thiol sugar. 
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  In addition to the general classes of NO donors, additional types of NO donors exist. In 
this study, ethanesulfohydroxamic acid (ESHA) was also tested as potential nitric oxide donor. 
From Figure 1.12, it is evident that ESHA has a very similar structure to that of SAHA and AHA 
sharing similar binding groups of a sulfonyl hydroxamic acid compared to a hydroxamic acid. 
This compound acts as a dual NO and HNO donor to inhibit enzymes.
32
 Sodium nitroprusside, 
shown in Figure 1.13, is potent and releases NO spontaneously in the form of a nitrosyl group 
bound to iron. This compound is used for treatment of hypertension and heart failure.
28
   
 
Figure 1.12: Structure of Ethanesulfohydroxamic acid.  
 
Figure 1.13: Structure of Sodium nitroprusside.  
 The uses of nitric oxide donors clinically as small molecule drugs are plentiful. The most 
studied actions of NO are in the cardiovascular system where it increases vasodilatation. Other 
uses of NO donors are their effects on the immune system to decrease cell proliferation, platelet 
aggregation and platelet adhesion. Additionally, NO donors have been shown to increase 
apoptosis and decrease cytokine release and they are also used for pain relief. 
28
 
Organic nitrates are the most common kind of NO donor drug; with glyceryl trinitrate, 
GTN (nitroglycerin) and isosorbide mononitrate (ISMN) being the most common. Both GTN 
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and ISMN are used for pain relief and to treat heat attacks (nitroglycerin).
33
 The chemical 
structures of both GTN and ISMN are shown in Figure 1.14. Another NO donor that is currently 
used is SNP, which provides rapid lowering of blood pressure which is used for patients with 
hypertension. It is also considered the gold standard for vasodilators. The chemical structure of 
SNP is shown in Figure 1.13. Currently no NONOates are being used clinically although DEA-
NONOate and DETA-NONOate are heavily studied for possible treatments of hypertension, lung 
injuries, erectile dysfunction, and thrombosis.
28
 Interestingly, NONOates have been receiving 
interest as a possible mode to deliver high concentrations of NO specifically to tumor cells.
33
 JS-
K, another NONOate, slows the growth of a wide range of cancer cells without harming healthy 
cells and is in clinical trials for treatment of leukemia.
29
 
   
Figure 1.14: Chemical Structures of GTN and ISMN.  
 S-nitrosothiols are more tissue specific than other types of NO donors and are also potent 
anti-platelet drugs that inhibit aggregation.
33
. S-nitroso-N-acetylpenicillamine (SNAP) has been 
shown to be useful in improving coronary endothelial function. S-nitroso-glutathione (GSNO) is 
used for selective treatment of arterial disorders, as opposed to treating both arteries and veins. It 
has also been shown to decrease the occurrence of cerebral embolisms, and to have 
neuroprotective properties by regulating the antioxidant and apoptotic pathways.  
 Nitric oxide donors also act as inhibitors of HDACs. The NO donors are hypothesized to 
interact with three cysteine residues on the HDAC surface (not in close proximity the active site) 
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to render it inactive. Current studies have used GSNO as an exogenous NO donor to inhibit 
HDACs.
34
 Interestingly, both SAHA and TSA release nitric oxide upon oxidation in the body 
and have been shown to not only inhibit HDACs by interacting with the active site but to also 
release NO that interacts with the protein surface.
35
 Nitric oxide acts on both nuclear and 
cytoplasmic HDACs and preliminary studies suggest that NO may prevent HDACs from 
assembling the necessary multi-protein complexes for its activity.
34
 
1.8 Fluorogenic Inhibition Assay 
 Enzyme assays are an analytical tool that determines an enzyme’s activity over time or at 
an endpoint. Enzyme assays play a critical role in the drug discovery process by determining if 
inhibition is taking place or if the enzyme activity has increased.
36
 One such assay that releases a 
fluorescent product upon reaction is called a fluorogenic assay. In general, this technique uses a 
substrate that has fluorogenic properties that change in proportion to the rate of cleavage from 
the enzyme. For proteolytic enzyme reactions, a fluorophore is adjacent to the site of proteolytic 
cleavage which in turn produces fluorescence. The fluorescent signal is directly proportional to 
the amount of substrate cleaved.
37
   
Specifically in the case of HDAC8, the assay most commonly used is a discontinuous 
coupled assay. The peptide substrate containing an acetylated lysine and a quenched fluorophore 
is deacetylated by HDAC8. After deacetylation, a developer solution containing a protease 
cleaves the peptide further which causes the release of the fluorophore. A general reaction 
scheme for this process is shown in Figure 1.15. While many types of fluorogenic substrates are 
available, we used 4-acetyl-L-Arg-L-His-L-Lys(ε-acetyl)-L-Lys(ε-acetyl)-coumarin (Fluor de Lys 
Substrate) for the assay.  This particular type of assay is a discontinuous endpoint assay, meaning 
that the fluorescence is not measured over time but rather at the endpoint of consecutive 
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reactions of HDAC8 followed by the protease in the developer solution. Based on the relative 
fluorescent units (RFUs) obtained for a particular reaction with inhibitor present compared to a 
control without inhibitor, it can be determined whether or not the enzyme is being affected. A 
decrease in RFUs indicates inhibition while an increase in RFUs points towards activation. These 
data are typically presented as percent activity, with the control serving as 100% activity.   
 
Figure 1.15: Reaction scheme of the HDAC8 Fluorimetric Activity Assay. Substrate is deacetylated by HDAC8and 
developer produces a fluorophore that is read at an excitation wavelength of 360nm and a emission wavelength of 
480 nm.
38
  
 
 While the exact mechanism is unknown, nitric oxide plays a role in the regulation of 
inflammatory pathways and in inflammatory cancers. Thus, this study was conducted to 
determine if HDACs are inhibited by nitric oxide donors. The information gathered here will be 
used to begin to understand the modes of HDAC inhibition and regulation through nitric oxide 
480 nm 360 nm 
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donors and potential drug targets for inflammatory cancers. To begin, we used a broad range 
concentration screening technique to determine whether or not HDAC8 is inhibited at high and 
low concentrations of SNP, SNAP, JS-K, DEA-NONOate, DETA-NONOate and L-CysNO. The 
NO donors that showed inhibitory properties were further tested using a tighter range of 
concentrations to try to determine the IC50. The IC50 or half maximal (50%) inhibitory 
concentration (IC) is a measure of the overall effectiveness of an inhibitor. The IC50 provides 
critical information on the potency of the inhibitor as well as information that is useful when 
determining the dosage of the drug candidate. Additional screens were performed using AHA, 
SAHA and ESHA to test their ability as inhibitors.  
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Chapter 2: Isothermal Titration Calorimetric Studies of 
SAHA and AHA Binding to Zn
2+ 
and Co
2+ 
 
 The interaction of SAHA and AHA with the transition metals zinc(II) and cobalt(II) were 
studied using ITC. From the resulting data, the binding parameters including the stoichiometry of 
binding (n), the equilibrium binding constant (Ka), the change in entropy (ΔS), the change in 
enthalpy (ΔH) and the standard change Gibb’s free energy (ΔG°) were determined. All the 
parameters were obtained at 25°C and at a pH of 6.80. The buffer used was an NEM buffer 
consisting of 50 mM NEM and 150 mM NaCl.  
 Suberoylanilide hydroxamic acid and AHA were titrated with zinc(II) and cobalt(II) to 
yield the thermodynamic binding parameters for each system. Zinc(II) was chosen because it is 
found at the active site of HDAC in vivo. Cobalt(II) was used because when zinc(II) in the active 
site of HDAC8 is replaced with cobalt(II) in vitro the enzyme still retains its activity allowing for 
an interesting point of comparison between the binding parameters.
20
  
  Suberoylanilide hydroxamic acid is insoluble in aqueous media but soluble in 
methanol.
39
 Titrations were therefore first carried out in anhydrous methanol. However, the data 
were not reproducible. Upon investigation it was determined that small, but possibly varying 
amounts of water were likely present in the methanol and in the ZnCl2 and CoCl2 solutions of 
metal ions. The variations in the ITC data obtained in methanol are likely a result of heats related 
to solvation and desolvation, which varies across solvent conditions.  
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 To counteract this problem, anhydrous methanol was aliquoted under nitrogen 
atmosphere. This resulted in smaller heats of binding but still unsatisfactory reproducibility. 
Finally, a mixture of methanol and buffer, was used to eliminate the interference of water in the 
solvent while still ensuring sufficient SAHA solubility.  Specifically, a mixture of 60% 
anhydrous methanol and 40% NEM buffer at pH 6.80 was found be suitable as it yielded 
reproducible results as long as the samples were not degassed. Degassing is a process where 
trapped air bubbles are removed from the solvent under a vacuum. Due to the volatile nature of 
methanol, degassing alters the methanol:buffer mixture composition and also the solute 
concentration, making data not reproducible. Therefore samples containing methanol were not 
degassed.  
2.1  SAHA- Zn
2+
 Binding in the Methanol: Buffer Mixture  
 The binding interaction of SAHA and zinc(II) was determined in the above mixture with 
10 mM SAHA being titrated into 1 mM zinc(II). Figure 2.1 shows raw data and the resulting 
binding isotherm for a sample SAHA into zinc(II) titration experiment. Figure 2.2 shows an 
overlay of the isotherms of three triplicate experiments. On the same figure, an isotherm of 
zinc(II) ion into the methanol:buffer mixture control experiment is shown.  A constant 
corresponding to the plateau value (the constant where the binding isotherm is at its flattest) of 
the resulting isotherm was subtracted as well.    
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Figure 2.1: Titration calorimetry of SAHA into zinc(II). A 10 mM solution of SAHA was titrated at 25°C, using 
injections of 10 µL, into a 1 mM solution of ZnCl2. Both were prepared in 60% anhydrous methanol and 40% buffer 
containing 50 mM NEM, 150 mM NaCl, pH 6.80.  
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Figure 2.2: Fitting of SAHA into zinc(II) isotherms. The three triplicate isotherms (open symbols) of 10 mM SAHA 
and 1 mM zinc(II) are shown with their corresponding best fit line. The methanol: buffer mixture into zinc(II) 
control (closed symbol) was subtracted from the binding isotherms before fitting the curve.  
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 The average binding parameters obtained when titrating SAHA into zinc(II) were an 
equilibrium constant of 4.3 ± 0.5 x10
2
 M
-1
, a ΔH of -8.0 ± 0.2 x103 cal/mol, a ΔS of -14.7 ± 0.6 
cal/mol·deg, a ΔG° of -15.0 ± 0.3 kJ/mol and a stoichiometry of binding fixed at 0.5 SAHA per 
zinc ion, as shown in Table 2.1 and 2.2. The fitting was not able to find a unique n-value, a 
consequence of the c-value being outside of the ideal window. However, when the n-value was 
fixed at 0.5 or lower the fit was equally as good when judged by the naked eye. It is also 
important to note that the data did not fit n-values of 1 or greater, which was determined by 
comparing the values obtained for the reduced chi-squared. The stoichiometry of binding 
represents the number of moles of titrate bound per titrate, thus the stoichiometry of 0.5 implies 
that two zinc(II) ions are bound per SAHA molecule.  
 The rationale behind the n-value of 0.5 is somewhat unclear but several factors may be 
contributing to this unexpected value. The first is that the concentration of SAHA could have 
been underestimated or the concentration or zinc(II) could have been over estimated due to 
massing errors. Either scenario would result in a smaller n-value. The solution concentrations 
will be verified using atomic absorption spectroscopy (experiment not yet conducted). The more 
likely reasoning behind this unexpected value is that the solubility of SAHA is low. Because of 
this, the concentration of SAHA could not be increased enough to be in the ideal c-value window 
of 1-1000. Figure 2.2 shows that the curves are nearly featureless (refer to Figure 1.7 for the 
shape of an ideal curve), which explains why the curve fitting is unable to pinpoint an n-value. In 
addition, the value of the subtracted plateau heat alters the n-value. However, it is worth noting 
that the variance in stoichiometry of binding does not significantly affect the equilibrium binding 
constant (determined through fitting the same curve with multiple n-values and comparing the 
equilibrium constants obtained.) 
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 The bond angle of the hydroxamic acid group on SAHA makes it extremely favorable to 
interact only with zinc(II), especially zinc(II) at the active site of HDAC.
40
 The fairly large 
equilibrium constant of 4.3 ± 0.5 x10
2
 M
-1
 suggests that the interaction of SAHA and zinc(II) is a 
strong interaction with little dissociation. Additionally, the ΔH value of -8.0 ± 0.2 x103 cal/mol 
suggests a very exothermic reaction where heat is being released to the surroundings. The 
negative ΔG° is consistent with the reaction occurring spontaneously under standard state 
conditions. These data were unavailable prior to this study.  
 In addition to thermodynamic binding data, this study provides valuable insight into the 
major energetic contributors of HDAC inhibition. The equilibrium constant of 4.3 ± 0.5 x10
2
 M
-1 
obtained in this study
 
is small in comparison to the equilibrium constant for SAHA and zinc at 
the active site of HDAC8, 1.72 x 10
6 
M
-1
.
16
 This seems to suggest that the other interactions of 
SAHA such as the van der Waals interactions with the hydrophobic tunnel and the interactions of 
the cap on the surface of the enzyme are the major contributors to the affinity of SAHA for the 
active site. To compare in terms of the energetic binding, the ΔG°, which has an additive 
relationship for contributions from different interactions rather than the multiplicative 
relationship of the affinity constant, was calculated from the Ka using Equation 6. The 
contribution of zinc binding seems to be more readily comprehended through the ΔG° for SAHA 
binding to zinc(II) of -15.0 kJ/mol as opposed to the ΔG° for SAHA interacting with the active 
site of HDAC8 of -35.6 kJ/mol.
16
 These values suggest that the binding of SAHA to zinc(II) 
contributes approximately 42% of the binding energetics of the overall SAHA and zinc(II)  
interaction.  
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2.2  SAHA-Co
2+
 Binding in the Methanol: Buffer Mixture  
 The binding interaction of 20 mM SAHA and 3 mM cobalt(II) was also determined in the 
same methanol: buffer mixture described above. Figure 2.3 shows sample data obtained for a 
SAHA into cobalt(II) titration experiment. Figure 2.4 shows an overlay of five replicate binding 
isotherms obtained under the same experimental conditions. The cobalt(II) controls and plateau 
heats were subtracted from each binding isotherm as described above.  
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Figure 2.3: Titration calorimetry of SAHA into cobalt(II). A 10 mM solution of SAHA and a 3 mM solution of 
cobalt (II)  were prepared in 60% anhydrous methanol and 40% 50 mM NEM, 150 mM NaCl buffer pH 6.80. SAHA 
was titrated into cobalt(II) at 25°C using 10 µL injections.  
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 The average binding parameters obtained for titrating SAHA into cobalt(II) were a 
stoichiometry of binding fixed at 0.50 SAHA per cobalt(II), an equilibrium binding constant of 
2.0 ± 0.5 x 10
2
 M
-1
, a ΔH of -5.6 ± 0.7 x 103 cal/mol, a ΔS of -8.5 ± 2.7 cal/mol·deg and a ΔG° 
of -13.1 ± 0.7 kJ/mol (Table 2.1 and 2.2). The stoichiometry of binding implies that two 
cobalt(II) ions are bound per SAHA molecule. This, like the SAHA-zinc(II) curves, is most 
likely due to the small c-value of approximately 0.3 causing the undesirable shape of the binding 
curves. This required the n-value to be fixed at 0.5 because when the curve was fit the program 
could not settle on a unique set of parameters. 
 Using cobalt(II) as a point of comparison, the fairly small equilibrium constant of 2.0 ± 
0.5 x 10
2
 M
-1
 suggests that the interaction of SAHA with cobalt(II) is approximately half the 
strength of the interaction between SAHA and zinc(II), which has an equilibrium constant of 4.3 
± 0.5 x10
2
 M
-1
.  While the stoichiometric ratio of SAHA and cobalt(II) and SAHA and zinc(II) 
are the same (1:2) the difference in equilibrium constants suggests that SAHA is bound more 
tightly to zinc(II) than it is to cobalt(II). These values imply that when using the same 
concentrations of zinc(II) and cobalt(II)  fewer SAHA molecules dissociated from zinc(II) than 
dissociated from cobalt(II). Additionally, the 110° bond angle of the hydroxamic acid favors 
zinc(II) due to its ideal orientation around zinc(II) to form a penta-coordinated ion.
41
 This seems 
to be a plausible reason as to why zinc(II) binds more strongly to SAHA than cobalt(II). Again, 
the calculated ΔG° of -13.1 ± 0.7 kJ/mol compared to the ΔG° of -15.0 ± 0.3 kJ/mol for SAHA 
and zinc(II) binding shows that cobalt(II) binding energetically contributes approximately 13% 
less than zinc(II) binding.  
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Figure 2.4: Fitting of SAHA into cobalt(II) isotherms. An overlay of the binding isotherms from three triplicate 
experiments of 20 mM SAHA into 3 mM cobalt(II) are shown (open symbols). The cobalt(II) controls (closed 
symbols) were averaged and then subtracted from the binding curves.  
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2.3 AHA-Zn
2+
 Binding in the Methanol: Buffer Mixture  
 To relate the binding parameters obtained for SAHA in the methanol: buffer mixture to 
more physiological conditions, we chose to also study the water, as well as methanol soluble 
compound AHA (Figure 2.5). Acetohydroxamic acid shares the chemical structure with the 
portion of SAHA (Figure 1.6) responsible for coordinating to zinc ions, the hydroxamic acid, in 
the active site of HDACs and is used in the literature as the prototype for hydroxamic acid 
binding. Acetohydroxamic acid interacting with zinc(II) and cobalt(II) was studied in both the 
solvent mixture and aqueous buffer. The difference between the data for AHA-metal binding in 
the solvent mixture compared to aqueous conditions was used to extrapolate SAHA-metal 
binding in buffer.  
 
Figure 2.5: Skeletal structure of acetohydroxamic acid. 
 
 The binding interaction of 20 mM AHA into 2 mM zinc(II) was determined in the 
methanol: buffer mixture. Figure 2.6 shows raw data and the resulting binding isotherm for a 
sample AHA into zinc(II) titration experiment. Figure 2.7 shows an overlay of the isotherms of 
five replicate experiments. On the same figure are two AHA controls, which were averaged and 
then subtracted from each of the binding curves. A plateau value was subtracted as described for 
previous titration experiments  
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Figure 2.6: Titration calorimetry of AHA into zinc(II). A 20 mM solution of AHA and a 2 mM solution of zinc(II) 
were prepared in 60% anhydrous methanol and 40% 50 mM NEM, 150 mM NaCl buffer pH 6.80. The AHA 
solutions were titrated at 25°C into zinc(II) using 10 µL injections.  
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 The average binding parameters obtained for 20 mM AHA and 2 mM zinc(II) are an n-
value of 0.52 ± 0.17 AHA per zinc(II), an equilibrium constant of 4.4 ± 0.8 x10
2
 M
-1
, a ΔH of -
8.6 ± 3.2 x10
3
 cal/mol, a ΔS of -17 ± 11 cal/mol∙deg and a ΔG° of -15.0 ± 0.5 kJ/mol (Table 2.1 
and 2.2). Acetohydroxamic acid is not a known HDAC inhibitor, thus the relevance of these data 
is not to determine the binding strength of AHA and zinc(II) compared to that of SAHA and 
zinc(II). Rather, these data will be compared to the data obtained for AHA and zinc(II) in buffer 
to establish if the parameters drastically change under the two different solvent conditions.  
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Figure 2.7: Fitting of AHA into zinc(II) isotherms. An overlay of the five replicate titrations of AHA into zinc(II) at 
the given concentration is shown with the open symbols. The AHA controls are shown with the closed symbols. The 
controls were averaged and then subtracted from each binding curve before fitting the curve.  
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2.4 AHA-Co
2+
 Binding in the Methanol: Buffer Mixture  
 
 
 The binding interaction of 20 mM AHA and 2 mM cobalt(II) was determined in the 
methanol:buffer mixture. Figure 2.8 shows raw data and the resulting binding isotherm for a 
sample AHA into cobalt(II) titration experiment. Figure 2.9 shows an overlay of the isotherms of 
five replicate experiments. The AHA controls as well as a plateau heat were subtracted as 
previously described.   
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Figure 2.8: Titration calorimetry of AHA into cobalt(II). A 20 mM solution of AHA and a 2 mM solution of 
cobalt(II) were prepared in 60% anhydrous methanol and 40% 50 mM NEM, 150 mM NaCl buffer pH 6.80. The 
AHA solutions were titrated into cobalt(II) at 25°C using 10 µL injections.  
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 The average binding parameters obtained for 20 mM AHA and 2 mM cobalt(II) are an n- 
value of 0.58 ± 0.12 AHA per cobalt(II), an equilibrium binding constant of 3.2 ± 0.4 x10
2
 M
-1
, a 
ΔH of -5.0 ± 1.2 x103 cal/mol, a ΔS of -5 ± 4 cal/mol∙deg and a ΔG° of -14.3 ± 0.4 kJ/mol (Table 
2.1 and 2.2). Like the data obtained for the interaction of AHA and zinc(II), these data were not 
used for determining binding strength of AHA and cobalt(II) compared to that of SAHA and 
cobalt(II) but rather to compare the interaction of AHA and the metal across the two solvent 
conditions.  
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Figure 2.9: Fitting of AHA into cobalt(II) isotherms. An overlay of the five replicate titration experiments of 20 
mM AHA into 2 mM cobalt(II) is shown (open symbols). The AHA controls are shown with the solid symbols. The 
controls were averaged and then subtracted from each binding curve before fitting the each isotherm.   
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2.5  AHA-Zn
2+
 Binding in Buffer  
 To determine the differences in the thermodynamic binding parameters between the 
methanol: buffer mixture and aqueous conditions, the interaction of 50 mM AHA and 5 mM 
zinc(II) was determined in NEM buffer. Figure 2.10 shows raw data and the resulting binding 
isotherm for a sample AHA into zinc(II) titration experiment. Figure 2.11 shows an overlay of 
the isotherms of four replicate experiments. The AHA controls and plateau heat was subtracted 
as described for previous titration experiments.   
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Figure 2.10: Titration calorimetry of AHA into zinc(II). A 50 mM solution of AHA and a 5 mM solution of zinc(II) 
were prepared in 50 mM NEM, 150 mM NaCl buffer pH 6.80. The AHA solutions were titrated into zinc(II) at 25°C 
using 10 µL injections.  
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 The average binding parameters obtained for 50 mM AHA and 5 mM zinc(II) are an n-
value of 0.51 ± 0.06 AHA per zinc(II), an equilibrium constant of 3.6 ± 0.4 x10
2
 M
-1
, a ΔH of  
-2.5 ± 0.2 x10
3
 cal/mol, a ΔS of 3.2 ± 0.3 cal/mol∙deg and a ΔG° of -14.6 ± 0.8 kJ/mol (Table 2.1 
and 2.3). When comparing the stoichiometry and equilibrium binding constants obtained in 
buffer to those obtained in the methanol: buffer mixture the n-value of 0.51 ± 0.06 
 
AHA per 
zinc(II) obtained in buffer and 0.52  ± 0.17 AHA per zinc(II) obtained in the methanol: buffer 
mixture agree. The equlibrium binding constants are also the same within error  between the 
methanol: buffer mixture and buffer; 4.4 ± 0.8 x 10
2
 and 3.6 ± 0.4 x 10
2
 M
-1
, respectively.  
 However, the ΔH and ΔS are vastly different between the two solvent conditions. These 
significant differences (ΔHbuffer= -2.5 ± 0.3 x10
3
 cal/mol, ΔSbuffer= 3.15 ± 0.75 x10
3
 cal/mol·deg, 
ΔHmixture= -8.6 ± 3.2 x10
3 
cal/mol, and ΔSmixture= -17 ±11 cal/mol·deg) can be attributed to both 
ΔH and ΔS depending on solvation and desolvation. The solvation and desolvation process 
differs from one solvent to another; in this case, the solvation enthalpy under aqueous conditions 
would be greater than in the methanol:buffer mixture for the polar moiety. Thus we would expect 
the equiblibrium constant to be larger in the mixture of solvents than in buffer. This is because 
the titrant and titrate have to forfeit less enthalpy to undergo desolvation to interact with each 
other. In addition, the idea of entropy-enthalpy compensation is observed in this system. This 
implies that although the values of entropy and enthalpy change between the two solvent 
conditions the relative difference between them is the same (i.e. a large negative enthalpy is 
accompained by a more negative entropy change and vice versa).  
 Overall, we can say that stoichiometry, binding affinity and ΔG° observed for AHA 
interacting with zinc(II) in the methanol: buffer mixture compared to those observed in buffer are 
the same. Because of this, the parameters for SAHA interacting with zinc(II) can be extrapolated 
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to buffer conditions. Based on the data obtained for the AHA zinc(II) interaction it is likely that 
the parameters acquired for the SAHA-zinc(II) interaction are very similar to what they would be 
if  SAHA were soluble in aqueous condtions.  
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Figure 2.11: Fitting of AHA into zinc(II) isotherms. An overlay of the four replicate experiments of 50 mM AHA 
into 5 mM zinc(II) is shown with the open symbols. The AHA controls are shown with the solid symbols. The 
controls were averaged and then subtracted from each binding curve before fitting the curve. 
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 In order to increase the c-value to better define the shape of the curve the concentrations 
of AHA and zinc(II) were doubled. This allowed for a more accurate determination of the 
binding parameters, especially the n-value. The experiments using the increased concentration 
were only able to be completed for AHA because SAHA has limited solubility under the chosen 
solvent conditions. Therefore, the binding interaction of 100 mM AHA and 10 mM zinc(II) was 
determined in buffer. Figure 2.12 shows raw data and the resulting binding isotherm for a sample 
AHA into zinc(II) titration experiment at the higher concentration. Figure 2.13 shows an overlay 
of the isotherms of two duplicate experiments. As described with previous titration experiments, 
the AHA controls and plateau heat was subtracted.   
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Figure 2.12: Titration calorimetry of AHA into zinc(II). A 100 mM solution of AHA and a 10 mM solution of 
zinc(II) were prepared in 50 mM NEM, 150 mM NaCl buffer pH 6.80. The AHA solutions were titrated into zinc(II) 
at 25°C using 5 µL injections. 
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 The average binding parameters obtained for 100 mM AHA and 10 mM zinc(II) are an n- 
value of 0.33 ± 0.06 AHA per zinc(II), an equilibrium binding constant of 6.5 ± 0.2 x10
2
 M
-1
, a 
ΔH of -2.5 ± 0.2 x102 cal/mol, a ΔS of 4.57 ± 0.69 cal/mol∙deg and a ΔG° of -16.1 ± 0.1 kJ/mol 
(Tables 2.1 and 2.3). When comparing the data obtained using 100 mM AHA and 10 mM 
zinc(II) to the data obtained using 50 mM AHA and 5 mM zinc(II) it seems that the n-value is 
signficantly less, even with the associated error; 0.51 ± 0.06 sites
 
obtained using 50 mM AHA 
and 5 mM zinc(II) compared to 0.33 ±0.06 sites obtained using 100 mM AHA and 10 mM 
zinc(II). The equilibrium binding constant is approximately doubled when the concentration of 
titrant and titrate are doubled, 3.4 ± 0.4 x 10
2 
M
-1 
using 50 mM and 5 mM compared to 6.5 ± 0.2 
x 10
2 
M
-1 
obtained using 100 mM and 10 mM. These differences using the two concentrations 
suggests that the parameters obtained using the higher concentrations are more accurate because 
the c-value is within the ideal range of 1-1000 (3.26 compared to 0.84 with the lower 
concentrations).  
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Figure 2.13: Fitting of AHA into zinc(II) isotherms. Overlays of the two duplicate titration experiments of 100 mM 
AHA into 10 mM zinc(II) are shown with closed symbols. The AHA controls are shown with open symbols. The 
controls were averaged and then subtracted from each isotherm before fitting the binding curve.  
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2.6 AHA-Co
2+
 Binding in Buffer 
 
 The binding interaction of 50 mM AHA and 5 mM cobalt(II) was determined in NEM 
buffer. Figure 2.14 shows raw data and the resulting binding isotherm for a sample AHA into 
cobalt(II) titration experiment. Figure 2.15 shows an overlay of the isotherms of three triplicate 
experiments. The AHA controls and plateau heat was subtracted as described for previous 
titration experiments.  
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Figure 2.14: Titration calorimetry of AHA into cobalt(II). A 50 mM solution of AHA and a 5 mM solution of 
cobalt(II) were prepared in 50 mM NEM, 150 mM NaCl buffer, pH 6.80. The AHA solutions were titrated into 
cobalt(II) at 25°C using 10 µL injections.  
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 The average binding parameters obtained for 50 mM AHA and 5 mM cobalt(II) are an n-
value of 0.26 ± 0.01 AHA per cobalt(II), an equilibrium constant of 2.1 ± 0.3 x10
2
 M
-1, a ΔH of -
7.2 ± 0.3 x10
3
 cal/mol, a ΔS of -13.5 ± 1.0 cal/mol∙deg and a ΔG° of -13.2 ± 0.1 kJ/mol (Tables 
2.1 and 2.3). The data obtained in buffer compared to the data obtained in the methanol: buffer 
mixture suggest that the values obtained between the two solvent condtions are not the same 
within error. However, a fitting with the n-value fixed at 0.5 also fits the data, although based on 
the reduced chi-squared, not as well as the curve that yielded the values stated previously. This 
implies that the curve is not unique enough to fit just one set of parameters due to the low c-
value of 0.27. Additionally, the equiblibrium binding constants of 3.0 ± 0.4 x10
2
 M
-1
 agree 
within error of the 3.2 ± 0.5 x10
2
 M
-1 
determined in the methanol:buffer mixture. Therefore, we 
concluded that the parameters obtained in the methanol:buffer mixture and in NEM buffer are 
comparable. Additionally, the thermodynamic binding parameters for the interaction of SAHA 
and cobalt(II) in buffer can be extrapolated, although these values are most likely not as accurate 
as those obtained from the interaction of SAHA and zinc(II). This is because the AHA-Co(II) 
parameters were not as agreeable between the two solvents as those obtained for AHA and zinc.  
Again, the entropy and enthalpy were not used as part of the comparision because they change 
with relation to other factors unrelated to the heat of binding.  
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Figure 2.15: Fitting of AHA into cobalt(II) isotherms. An overlay of the three duplicate titration experiments of 50 
mM AHA into 5 mM cobalt(II) is shown with the open symbols. The AHA controls are shown with the closed 
symbols. The controls were averaged and then subtracted from each isotherm before fitting the curve. Another run 
was performed using the same conditions but was not shown on the curve because it looked identical to the previous 
runs. 
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 To confirm the binding parameters and determine whether or not the different injection 
order (i.e. higher local concentration of AHA rather than cobalt(II)) results in a different binding 
mode, cobalt(II) was titrated into AHA, the opposite of the previous runs. Thus the binding 
interaction of 50 mM cobalt(II) into 5 mM AHA was determined in buffer. Figure 2.16 shows 
raw data and the resulting binding isotherm for a sample cobalt(II) into AHA titration 
experiment. Figure 2.17 shows an overlay of the isotherms of three triplicate experiments. The 
cobalt control and plateau heat were subtracted as previously described. It is important to note 
that this type of experiment could not be conducted using zinc because of its limited solubility 
under the chosen solvent conditions. 
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Figure 2.16: Titration calorimetry of Cobalt(II) into AHA. A 50 mM solution of CoCl2 and a 5 mM solution of 
AHA were prepared in 50 mM NEM, 150 mM NaCl buffer pH 6.80. The cobalt(II) solutions were titrated into AHA 
at 25°C using 10 µL injections. 
 
58 
 
 The average binding parameters obtained when titrating 50 mM cobalt(II) and 5 mM 
AHA are an n-value of 0.23 ± 0.08 cobalt(II) per AHA, an equilibrium binding constant of 2.8 ± 
0.6 x10
2
 M
-1
, a ΔH of -7.8 ± 2.2 x103 cal/mol, a ΔS of -15.1 ± 7.9 cal/mol·deg and a ΔG° of -
13.9 ± 0.5 kJ/mol (Tables 2.1 and 2.3). When comparing these data to the data obtained when 
titrating AHA into cobalt(II), the values for Ka are within error of each other. However, the 
stoichiometry of binding, is changed significantly when the local concentration of AHA and 
cobalt(II) are changed. This could be caused by an actual shift in the binding mode or simply just 
error with the experiment or an error in the data analysis caused by the low c-value due to 
solubility constraints. Despite the differences in the n-value, the affinity is the same and is not 
dependent on the local concentration of one molecule over the other. This suggests that the 
equilibrium binding constant obtained for AHA and cobalt(II) in buffer is reliable.  
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Figure 2.17: Fitting of Cobalt(II) into AHA isotherms. An overlay of the three triplicate experiments of 50 mM 
CoCl2 into 5 mM AHA is shown with the open symbols. The cobalt(II) control is shown with solid symbols. The 
control was subtracted from each isotherm before fitting the curve.  
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2.7  Summary of Binding Parameters 
 A summary of the experimental conditions and average thermodynamic binding 
parameters is shown in Table 2.1. All errors are reported as standard deviations calculated from 
two, three, four or five trials. For experiments where there is no standard deviation reported for 
the n-values, it was fixed at the given number (typically 0.5) to yield the lowest reduced chi-
squared for the curve.   
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Table 2.1: Summary of Run Conditions and Average Thermodynamic Binding Parameters.   
Solvent Conditions Titrant 
 
Titrate Average Thermodynamic 
Binding Parameters 
60% anhydrous 
methanol and 40% 50 
mM NEM, 150 mM 
NaCl buffer pH 6.80 
10 mM SAHA 1 mM ZnCl2 n = 0.50 (fixed) sites 
K= 4.3 ± 0.5 x10
2
 M
-1 
ΔH= -8.0 ± 0.2 x103 cal/mol 
ΔS= -14.7 ± 0.6 cal/mol·deg 
ΔG°= -15.0 ± 0.3 kJ/mol 
20 mM SAHA 3 mM CoCl2 n = 0.50 (fixed) sites 
K= 2.0 ± 0.5 x10
2
 M
-1 
ΔH= -5.6 ± 0.7 x103 cal/mol 
ΔS= -8.5 ± 2.7 cal/ mol·deg 
ΔG°= -13.1 ± 0.7 kJ/mol 
20 mM AHA 2 mM ZnCl2 n =0.52 ± 0.17 sites 
K= 4.4 ± 0.8 x10
2 
 M
-1 
ΔH= -8.6 ± 3.2 x103 cal/mol 
ΔS= -17± 11 cal/ mol·deg 
ΔG°= -15.0 ± 0.5 kJ/mol 
20 mM AHA 2 mM CoCl2 n = 0.58 ± 0.12 sites 
K= 3.2 ± 0.4 x10
2
 M
-1 
ΔH= -5.0 ± 1.2 x103 cal/mol 
ΔS= -5 ± 4 cal/ mol·deg 
ΔG°= -14.3 ± 0.4 kJ/mol 
50 mM NEM, 150 
mM NaCl buffer pH 
6.80 
50 mM AHA 5 mM ZnCl2 n = 0.51 ± 0.06 sites 
K= 3.6 ± 0.4 x10
2
 M
-1 
ΔH= -2.5 ± 0.2 x103 cal/mol 
ΔS= 3.2 ± 0.8 cal/ mol·deg 
ΔG°= -14.6 ± 0.3 kJ/mol 
100 mM AHA 10 mM ZnCl2 n = 0.33 ± 0.06 sites 
K= 6.5 ± 0.2 x10
2
 M
-1 
ΔH= -2.5 ± 0.2 x 103 cal/mol 
ΔS= 4.57± 0.69 cal/ mol·deg 
ΔG°= -16.1 ± 0.1 kJ/mol 
50 mM AHA 5 mM  CoCl2 n = 0.26 ± 0.01 sites 
K= 2.1 ± 0.3 x 10
2
 M
-1 
ΔH= -7.2 ± 0.3 x103 cal/mol 
ΔS= -13.5± 1.0 cal/ mol·deg 
ΔG°= -13.2 ± 0.1 
50 mM CoCl2 5 mM AHA n = 0.23 ± 0.08 sites 
K= 2.8 ± 0.6 x 10
2
 M
-1 
ΔH= -7.8 ± 2.2 x 103 cal/mol 
ΔS= -15.1 ± 7.9 cal/ mol·deg 
ΔG°= -13.9 ± 0.5 kJ/mol 
N is the number stoichiometric binding sites on the titrant, K is the equilibrium binding constant, ΔH is the change 
in enthalpy and ΔS is the change in entropy and ΔG° is the change in Gibbs free energy.  
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 Tables 2.2 and 2.3 show the parameters obtained under each solvent condition. These 
data were previously unavailable prior to this study. As stated earlier, the parameters obtained for 
AHA were used to determine if the thermodynamic parameters for SAHA could be extrapolated 
into aqueous conditions. Table 2.2 shows the parameters obtained for the interaction of AHA 
with zinc(II) and cobalt(II) as well as the interaction of SAHA with zinc(II) and cobalt(II) in the 
methanol: buffer mixture. Table 2.3 shows the parameters obtained for the interaction of AHA 
with zinc(II) and cobalt(II) in NEM buffer. Using the parameters and associated errors it can be 
seen that the values obtained in the two different solvents agree. These conclusions are what 
allow the interactions with SAHA with the metal ions in NEM buffer to be extrapolated. Based 
on this, the parameters obtained for the interaction of SAHA with zinc(II) and cobalt(II) in the 
methanol: buffer mixture are most likely within error of what they would be in buffer.    
 
Table 2.2: Summary of Thermodynamic Binding Parameters Obtained in the 60% Methanol 40% Buffer 
Mixture.   
Titrant Titrate N 
(sites) 
K 
(M
-1
) 
ΔH 
(cal/mol) 
ΔS 
(cal/mol·deg) 
ΔG° 
(kJ/ mol) 
SAHA Zn 0.5 (fixed)* 4.3 ± 0.5 x10
2 
-8.0 ± 0.2 x10
3
 -14.7 ± 0.6 -15.0 ± 0.3 
Co 0.5 (fixed)* 2.0 ± 0.5 x10
2 
-5.6 ± 0.7 x10
3
 -8.5 ± 2.7 -13.1 ± 0.7 
AHA Zn 0.52 ± 0.17 4.4 ± 0.8 x10
2 
-8.6 ± 3.2 x10
3
 -17 ± 11 -15.0 ± 0.5 
Co 0.58 ± 0.12 3.2 ± 0.4 x10
2 
-5.0 ± 1.2 x10
3
 -5 ± 4 -14.3 ± 0.4 
*Curve is not unique enough to yield a unique set of binding parameters  
 
Table 2.3: Summary of Thermodynamic Binding Parameters Obtained in Buffer. 
Titrant Titrate N  
(sites) 
K  
(M
-1
) 
ΔH  
(cal/mol) 
ΔS 
(cal/mol·deg) 
ΔG° 
(kJ/ mol) 
AHA Zn 0.51 ± 0.06 3.4 ± 0.4 x10
2
 -2.5 ± 0.2 x10
3
 3.2 ± 0.8 -14.6 ± 0.3 
0.33 ± 0.06 6.5 ± 0.2 x10
2
 -2.5 ± 0.2 x10
3
 4.6 ± 0.7 -16.1 ± 0.1 
Co 0.26 ± 0.01 2.1 ± 0.3 x10
2
 -7.5 ± 0.3 x10
3
 -13.5 ± 1.0 -13.2 ± 0.1 
Co AHA 0.23 ± 0.08 2.8 ± 0.6 x10
2
 -7.8 ± 2.2 x10
3
 -15.1 ± 7.9 -13.9 ± 0.5 
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2.8 Final Remarks 
 There were several problematic steps within this set of ITC experiments. First, the poor 
solubility of SAHA in aqueous solution forced us to turn to methanol as the solvent which is not 
a physiological solvent. The methanol: buffer mixture at pH 6.80 was a step closer towards a 
physiologically relevant condition and it effectively reduced the baseline noise, a problem that 
plagued the signals in titrations using 100% methanol. Other ratios of solvent mixtures were not 
examined in this work but the differences in the binding energetics obtained in the methanol: 
buffer mixture and in NEM buffer were insignificant. This suggests that slight variations in the 
solvent percentages do not make a significant contribution to the resulting parameters.  
 Another problem encountered was the effect of degassing samples prepared in methanol 
on data reproducibility. Degassing is normally necessary to remove trapped air, preventing heat 
spikes that can result from air bubbles as they get dislodged during a titration experiment. 
Degassing thus lowers the signal-to-noise level and increases accuracy of the resulting binding 
parameters. However, degassing became problematic for samples prepared in methanol or in the 
methanol: buffer mixture due to the volatile nature of methanol. Degassing significantly changes 
the composition of the solvent, i.e. the solvent is no longer 60% methanol and 40% buffer, and 
also changes the overall concentration of the solute by reducing the total volume. To avoid these 
complications, the samples prepared in the methanol: buffer mixture were not degassed. This 
proved to more than compensate for the disadvantage of an occasional air bubble due to not 
degassing.  
 Initially, we planned on examining the binding interaction of SAHA to zinc(II) and 
copper(II). The poor solubility of copper(II) also posed a challenge because  copper(II) was not 
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soluble enough in NEM buffer or the mixture (both at pH 6.80) to yield the minimum 
concentration needed for the ITC experiments. Cobalt(II) ion was chosen instead. For the future, 
if the interaction of copper (II) with SAHA or other HDAC inhibitors is to be studied using ITC, 
different solvent ratios, different buffers and different pH values could be tested until a high 
enough solubility is reached.  
 The hygroscopic nature of AHA was also a problem. When a molecule is hygroscopic it 
immediately absorbs water from the air it is exposed to thereby altering the molecular formula 
weight of the compound. This makes it extremely difficult to mass out an accurate amount of 
AHA. To counteract this physical property of AHA, it was removed in small portions under 
nitrogen atmosphere and the bottles were then sealed to avoid air contact. When solutions were 
made, the solid was massed as quickly as possible to try to limit the amount of water absorbed by 
the compound. Once the bottle was opened and the required amount was removed for solution 
preparation, the remaining AHA in the bottle was discarded. 
 Another factor examined was the stability of SAHA and AHA under the chosen solvent 
conditions. Currently, the solution stability data of SAHA and AHA is not readily available. 
However, it is well known that the hydroxamic group is relatively unstable and the hydrolysis of 
this functional group results in a hydroxyl amine and a carboxylic acid. To ensure that the results 
obtained in these studies was a direct result of a binding interaction between AHA or SAHA and 
zinc(II) or cobalt(II), fresh solutions of AHA and SAHA were prepared and used no more than 
25 minutes before beginning the titration experiment. This was done to ensure that the majority 
of the solution was composed of fully intact molecules. The additional runs obtained using fresh 
SAHA or AHA did not differ significantly from runs using much older solutions. This evidence 
implies that the binding curves obtained are a result of the binding interaction between the metal 
65 
 
and the hydroxamic acid group. The runs using freshly prepared solutions were incorporated 
when calculating the average binding parameters for each system. Additionally, titration 
experiments using a mixture of the hydrolysis products of AHA (hydroxyl amine and acetic acid) 
and zinc(II) or cobalt(II) were completed. The binding curves obtained from the runs using the 
hydrolysis products were compared to previous runs using AHA. These curves show that the 
degradation products of AHA look like control experiments with small heats of binding that are 
constant throughout the entire titration experiment. This implies that the binding isotherms are a 
result of a binding interaction between the metal ion and the intact AHA or SAHA molecules, 
not between the metal ion and the hydrolysis products or the heat related to the hydrolysis of 
AHA or SAHA (data not shown).   
 The quality of the data may be improved if the percentage of buffer in the solvent mixture 
was increased. This may allow for less baseline noise and the ability to obtain reproducible 
results easily. Additional experiments to determine the highest percentage of buffer (in a 
methanol:buffer mixture) that solubilizes SAHA would be beneficial knowledge, as the increased 
solubility of SAHA could allow for a more reliable binding curve. Currently the c-value is 
between 0.20 and 0.30 which is well outside of the desired range. This introduced significant 
error when determining the binding parameters because the resulting curves lack the unique 
characteristics to fit one set of parameters. Increasing the c-value to be within the 1-1000 range 
would increase the accuracy of the binding parameters extracted, especially the binding 
stoichiometry. However, a significant increase in SAHA solubility would need to occur in order 
to be within the desired range of c-values. The concentration within the cell would need to be 5 
mM which means that the concentration of SAHA in the syringe would need to be approximately 
50 mM. Currently, under the chosen solvent conditions the maximum solubility of SAHA is 20 
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mM. Perhaps exploring other buffers, a lower salt concentration or different pH would affect the 
solubility and allow SAHA to become more soluble thereby increasing the reliability of the 
binding parameters obtained.   
 Future directions of this project would be to express and purify an HDAC isoform in a 
high enough quantity that ITC experiments using the protein and SAHA could be done. This 
would be valuable data that could be used to directly determine the binding affinity of SAHA. 
Another future direction is to test other hydroxamic acid inhibitors of HDAC such as 
Trichostatin A (TSA) or using other analogs of SAHA to determine the variations in the binding 
energetics. These data would be valuable because no thermodynamic binding data is available 
for these types of inhibitors. The binding energetics data obtained would be invaluable to design 
better inhibitors en route to the development of anti-cancer therapeutics.. 
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Chapter 3: Fluorogenic Assays of HDACs and 
Small Molecule NO Donor Inhibitors 
 
To determine if HDAC8 is inhibited by the selected nitric oxide donors which covalently 
modify free cysteine residues on the solvent exposed surface, a discontinuous fluorogenic assay 
of HDAC8 was performed. A broad range inhibitor screen (10 and 100 µM) was done to 
determine if and at what potency the NO donors were inhibiting the enzyme. These 
determinations were based off a 7-amino-4-methylcoumarin (AMC) standard curve. Once 
screened, NO donors were selected based on their percent inhibition and a tighter range 
screening was conducted to try and determine the half maximal inhibitory concentration (IC50) 
for the commercial NO donors. Additional screens of synthesized compounds, S-nitrosocysteine 
and ethanesulfohydroxamic acid as well as commercially available SAHA and AHA were 
performed. Overall only SAHA showed inhibitory effects on HDAC8.  
3.1 Constructing an AMC Standard Curve 
The deacetylation assay of HDAC8 produces the fluorescent molecule 7-amino-4-
methylcoumarin (AMC), after deacetylation and subsequent cleavage by the developer. The 
chemical structure of AMC is shown in Figure 3.1. We can accurately determine the 
concentration of AMC produced during a reaction because the concentration is relative to the 
RFUs (relative fluorescent units). The RFUs are dependent upon the settings of individual 
instruments deeming it necessary to prepare our own standard curve.  The equation of the line, 
                  for the standard curve of RFUs versus the concentration of AMC was 
used to calculate the amount of AMC produced once HDAC8 was exposed to the NO donors. 
The standard curve, represented in Figure 3.2, contains concentrations ranging between 0 and 10 
µM. This is sufficient to cover the experimental assays. Even though each well had 25 µM 
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AMC-containing substrate, significantly less free AMC was produced (< 10 µM) after reaction 
with HDAC8.  
 
Figure 3.1: Chemical Structure of AMC.   
 
 
Figure 3.1: AMC Standard Curve. The points on the curve represent 0, 0.5, 1 and 10 µM AMC in DMSO 
in the HDAC8 assay buffer at pH 8.0. The linear trend line of y=0.000150x+ 0.113 is reliable as 
determined by the R
2 
value close to 1.0 implying a  linear fit.  
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3.2 Screening Nitric Oxide Donors 
 In order to determine if any of the commercially available nitric oxide donors are possible 
inhibitors of HDAC8 a broad concentration assay using inhibitor concentrations of 100 µM and 
10 µM was completed.  Table 3.1 shows the results which include the concentration of AMC 
produced during the assay and the percent activity of HDAC remaining as compared to the 
control HDAC8 reaction. 
Table 3.1: Broad Range Inhibition Screen of Commercial NO Donors.  
Inhibitor 
100 µM 
RFUs [AMC] 
µM 
%  
Activity 
Inhibitor, 
10 µM 
RFUs [AMC] 
µM 
% 
Activity  
SNAP 3062 0.7254 81 SNAP 2677 0.6484 72 
SNP 2467 0.6064 67 SNP 2813 0.6756 75 
DEA 2851 0.6832 76 DEA 2345 0.5820 65 
JS-K 2365 0.5860 65 JS-K 3612 0.8354 93 
Control 3932 0.8994 100  
Screening performed using 400 nM HDAC8 in each well.  
 
 Based on the data in Table 3.1, the inhibitors that resulted in the lowest percent activity of 
HDAC8, or the greatest amount of enzymatic inhibition, were 10 µM DEA and 100 µM JS-K 
both with percent activities of 65%. Therefore, a smaller range of concentrations for these two 
inhibitors were screened with the goal of determining the IC50 for each inhibitor. More detailed 
screens of SNP and SNAP were performed because they are well known nitric oxide donors that 
inhibit a variety of enzymes. An additional assay using the NO-donor S-nitrosocysteine was also 
performed. Figure 3.3 shows the results of the more detailed screen using JS-K. At the high 
concentrations of 150 and 125 µM, a small extent of inhibition occurred, as observed though the 
percent activities of 86% and 63%, respectively. These are extremely high concentrations and are 
not considered relevant in drug discovery as typically, to be considered a potential drug 
candidate the potency must be below 10 µM.  Figure 3.4 shows that DEA NONOate activated 
rather than inhibited HDAC8. This is evident though the percent activities ranging from 105% to 
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153%. These results suggest that the screens performed (Table 3.1) were not reliable because 
they were not performed in replicate.  
 
Figure 3.3: Activation of HDAC8 with DEA NONOate. A plot of inhibitor concentration versus the percent 
HDAC8 activity remaining relative to a DMSO control. Varying concentrations of DEA NONOate between 20 µM 
and 5 µM and 400 nM HDAC8 were screened in triplicate. The RFUs measured were averaged. Error bars are 
calculated using root mean square error.  
 
 
 
Figure 3.4: Weak Inhibition of HDAC8 using JS-K. A plot of inhibitor concentration versus the percent HDAC8 
activity remaining relative to a DMSO control. Varying concentrations of JS-K between 150 µM and 75 µM and 400 
nM HDAC8 were screened in triplicate. The RFUs were measured and averaged. Error bars are calculated using 
root mean square error. 
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 The assays in Figures 3.3 and 3.4 were performed using 400 nM HDAC8 which is very 
high for medium-to-high throughput 96-well plate assays. To optimize the assay conditions and 
conserve enzyme, a control assay of HDAC8 using varying concentrations between 25 and 400 
nM was conducted to determine the lowest concentration of HDAC8 required for visible activity. 
Table 3.2 shows that the enzyme at all concentrations used were visibly active. Thus, the 
concentration of HDAC was reduced to 25 nM for subsequent assays to conserve enzyme. 
However, in the presence of the lower concentration of HDAC, the NO donors still yielded 
significant activation rather than inhibition as shown in Figure 3.5.  
 
Table 3.2: Optimization of HDAC8 Concentration. 
[HDAC8](nM) RFUs [AMC] (µM) 
400 2216 0.556 
333 1405 0.394 
166 1043 0.322 
83.6 947 0.302 
41.8 863 0.286 
25 852 0.283 
 
 
 
72 
 
   
Figure 3.5: Activation of HDAC8 with Nitric Oxide Donors. A plot of inhibitor concentration versus the percent 
activity of HDAC8 relative to a DMSO control. Varying concentrations of a nitric oxide donor inhibitor in µM were 
incubated with 25 nM HDAC8 and the fluorescence in RFUs of the triplicate wells were averaged. Inhibitor 
abbreviations are as follows:  S-nitrosocystene (L-Cys-NO), Sodium nitroprusside (SNP), and S-nitroso-N-acetyl-
penacillamine (SNAP). Error bars were calculated using root mean square error.  
 
 The results in Figure 3.5 were suspicious because these are all well known NO donors 
that were expected to show slight inhibition. The large error bars shown in Figure 3.5 indicate 
that the results are unreliable because most points have error bars ranging from as low at 50% 
activity all the way up to 250% activity.  This large range does not allow us to conclusively 
comment on the effectiveness of the inhibitors. To verify these results, a repeat screening of SNP 
was conducted. This assay yielded even higher percent errors suggesting there was a flaw in the 
assay itself. Therefore, two controls were performed; one using the normal incubation procedure 
of HDAC8 and inhibitor at room temperature and the other on ice. The results of this assay 
showed that there were no differences in the observed RFUs between the two controls suggesting 
that the incubation at room temperature was not the issue. (results not shown). An additional 
control assay was conducted to determine the background fluorescence of HDAC8. This assay 
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showed that the enzyme had slight fluorescence but not a significant amount (results not shown). 
Based on these data it was concluded the HDAC8 activity was too low to accurately monitor the 
activity; suggesting the enzyme may have become inactivated due to multiple freeze and thaw 
cycles.  
Using a newly acquired enzyme sample, a repeat screen of SNP using 25 nM HDAC was 
conducted. Table 3.3 shows the data obtained using concentrations of SNP between 150 µM and 
10 µM with 25 nM HDAC8. Again, no inhibitory activity was observed which is evident from 
the data in Table 3.3 which shows that the lowest percent activity value was 97%. In 
combination with the initial broad screening results, this suggests that an increased concentration 
of HDAC is required to reproducibly visualize enzymatic activity.  
Table 3.3: SNP Assay Using New HDAC8. 
[Inhibitor] (µM) RFUs [AMC] (µM) % activity 
0 159 0.145 100 ± 27 
150 142 0.142 98 ± 22 
110 135 0.140 97 ± 24 
80 155 0.144 99 ± 22 
40 157 0.144 100 ± 28 
10 139 0.141 97 ± 19 
Assay was set up using 25 nM HDAC8. Error is reported as root mean square error. 
At low enzyme concentration with the same amount of substrate (25 µM), the enzyme is 
in the presence of a higher ratio of substrate than if an optimized concentration of HDAC8 (400 
nM ) was used. Because the IC50 values are unknown, it is beneficial to prevent flooding the 
enzyme with substrate by having a greater ratio of enzyme to substrate; if the enzyme is saturated 
with substrate then the likelihood of inhibition decreases because the enzyme is going to act on 
the substrate (which is present in higher concentration) than the NO donor. Thus, the 
concentration of HDAC8 was increased to 100 nM to ensure that the ratio of enzyme to substrate 
was higher. In addition, because SNP, JS-K and DEA NONOate did not show evidence of 
significant inhibition, additional NO donor functional groups were tested. A known inhibitor of 
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HDAC, suberoylanilide hydroxamic acid, or SAHA, a small molecule hydroxamic acid 
acetohydroxamic acid, or AHA, SNAP and L-CysNO were used in this screening. Table 3.4 
shows the results of these screens. Despite the use of a higher concentration of enzyme no 
significant inhibition was observed. Table 3.4 shows that even SAHA, a potent, known inhibitor 
of HDACs showed only slight inhibition, as evidence by the percent activities ranging from 83% 
to 104%. Additionally, the percent activities for AHA ranged from 90% all the way up to 115% 
and L-CysNO had percent activities ranging from 90% to 103%. 
Table 3.4: SAHA, AHA, and SNP Screening. 
  [Inhibitor] (µM) Average RFUs [AMC] (µM) % Activity 
Control 0 898 0.293 100 ± 23 
SAHA 
 
 
 
 
150 643 0.242 83 ± 14 
110 810 0.275 94 ± 38 
80 869 0.287 98 ± 29 
40 955 0.304 104 ± 76 
10 815 0.276 94 ± 29 
AHA 
 
 
 
 
150 1070 0.327 112 ± 29 
110 1110 0.335 115 ± 20 
80 787 0.270 92 ± 58 
40 1023 0.318 108 ± 23 
10 746 0.262 90 ± 28 
SNAP 
 
 
 
 
150 766 0.266 91 ± 23 
110 804 0.274 94 ± 23 
80 938 0.301 103 ± 36 
40 753 0.264 90 ± 23 
10 824 0.278 95 ± 29 
Data collected using 100 nM HDAC8 enzyme. Reported error values are shown as root mean square error. 
It is hypothesized that the absence of inhibition observed in previous assays was a 
consequence of using too low an enzyme concentration. Thus, the results obtained from the 
assays using concentrations of enzyme other than 400 nM are unreliable. Once the concentration 
of HDAC was increased to the originally tested concentration 400 nM, L-CysNO, SNAP and 
ESHA, a sulfonyl derivative of a hydroxamic acid yielded inconclusive evidence on whether or 
not inhibition was occurring due to large  percent errors. However, SAHA, which has been 
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shown to act as both a competitive active site inhibitor as well as an NO donor upon oxidation in 
the body, showed strong evidence of inhibition as the percent activity using only 40 µM SAHA 
was 35% (Table 3.5) This could be indirect evidence supporting a dual inhibitory mechanism 
through active site competitive inhibition and release of nitric oxide. 
35
 However, these studies 
did not determine how much inhibition is caused by competitive inhibition and how much is 
caused by the release of NO. The percent activities observed using SNAP, L-CysNO, and ESHA 
at 400 nM enzyme seems to be suggest that the interaction of these small molecule inhibitors is 
weak under the chosen assay conditions as evidence by the minimal decreases in percent activity 
as well as the large associated errors.   
Table 3.5: SAHA, ESHA, L-CysNO and SNAP Screening. 
  [Inhibitor] (µM) RFUs [AMC] (µM) % activity 
Control 0 2053 0.0464 100 ± 10 
SAHA 150 588 0.0133 29 ± 4 
 
110 616 0.0139 30 ± 3 
 
80 875 0.0198 43 ± 17 
 
40 727 0.0164 35 ± 3 
SNAP 150 2225 0.0503 108 ± 7 
 
110 2282 0.0516 111 ± 8 
 
80 2162 0.0489 105 ± 12 
 
40 1922 0.0434 94 ± 9 
L-CysNO 150 1932 0.0437 94 ± 6 
 
110 1852 0.0418 90 ± 13 
 
80 2379 0.0538 116 ± 12 
 
40 2096 0.0474 102 ± 11 
ESHA 150 1347 0.0304 66± 38 
 
110 1487 0.0336 72 ± 28 
 
80 1436 0.0325 70 ± 20 
  40 2659 0.0601 130 ± 38 
 Data collected using 400 nM HDAC8. The error is reported as a root mean square error percentage.  
3.3  Final Remarks 
Overall, this study shows that the commercially available NO donors tested did not 
inhibit HDAC8 under the chosen assay conditions. Suberoylanilide hydroxamic acid, a positive 
control due to the fact that it is a known HDAC inhibitor, did inhibit strongly. This is 
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exemplified by the percent activities of HDAC8 ranging between 29% and 43%. Figure 3.6 
shows the surface structure of HDAC8. There are 10 cysteine residues present in the protein with 
3 exposed to the surface. None of the cysteines are involved in disulfide bonds. In addition, 
Figure 3.6 shows that most of them are buried within the protein and are not accessible to the 
solvent and therefore not accessible to nitric oxide. Nitric oxide inhibition occurs through 
covalent modification of solvent exposed free sulfhydryl groups on cysteine residues. The low 
number of solvent exposed cysteine residues could be the main explanation of why only the 
hydroxamic acid and sulfonyl derivative showed any inhibition.  
 
  
Figure 3.6: Surface Structure of HDAC8 with Labeled Cysteine Residues. Figure of surface diagram of PDB 
structure 1T69 visualized using Pymol. Structure on left and right are a 180° rotation of each other.  
 
 
In future studies, the assay could be further optimized using a lower concentration of both 
substrate and enzyme to lower the overall cost of the assay. Furthermore, a reducing agent such 
as dithiothreitol (DTT) or tris(carboxyethyl) phosphine (TCEP) could be added to the reaction 
mixture. This would be useful because while there are no structural disulfide bonds present in the 
protein, disulfides readily form in air under oxidizing conditions when cysteine residues are close 
enough in space making them much more stable. By adding the reducing agent to the mixture it 
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would prevent the cysteine residues that are exposed to the surface from being oxidized into 
disulfide bonds. Screening of additional NO donor compounds such as a known effective NO 
donor for histone deacetylases, GSNO, could be done to determine its inhibitory strength. 
Overall the development of a new assay for HDACs that is continuous and does not use a 
cysteine protease would be extremely beneficial to furthering assays using HDACs. The assay 
we used likely contains a cysteine protease because it cleaves after lysine residues in the 
substrate. The use of a cysteine containing protease is going to affect the assay because it 
contains an extremely reactive cysteine so the NO donor will likely act on that reactive cysteine 
as opposed to the cysteine residues in HDAC8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
  
Chapter 4: 
Experimental Methods 
 
4.1 Isothermal Titration Calorimetry   
a. General Considerations 
 Stock solutions of each component (SAHA, AHA, ZnCl2 and CoCl2) were prepared using 
stoichiometric calculations to determine the grams required to prepare the solution. All solutions 
were prepared using the highest grade of purity reagents available. The transition metals zinc(II) 
(II) chloride, 99.99%, extra pure was purchased from Acros Organics and cobalt(II) (II) chloride, 
98%, ACS reagent was purchased from Sigma-Aldrich. The HDAC inhibitor suberoylanilide 
hydroxamic acid was purchased from Fischer Scientific. Acetohydroxamic acid, 98+% was 
purchased from Acros Organics. All reagents were massed on the Ohaus analytical standard 
balance. The pH meter was calibrated using buffer solutions at pH 4.00±0.01, 7.00±0.01, and 
10.00±0.02 purchased from Fischer Scientific. The buffer was prepared using MilliQ water with 
a purity of ≤ 18 MΩ. The methanol: buffer mixture was prepared using 99.8% pure anhydrous 
methanol removed under nitrogen atmosphere.  All solution pHs were corrected using the Orion 
pH meter (model 420A). The Rainin p1000, p200, p20 and p10 pipettemen were for removing 
small volumes. Stock solutions were prepared in 50 mL and 15 mL Fischer brand disposable 
centrifuge tubes. Stock solutions were mixed on the Maxi Mix II Thermolyne Type 37600 mixer. 
Samples were degassed using the Thermovac (GE, formerly MicroCal, Piscataway, NJ). All 
calorimetric measurements were carried out using a VP-ITC Isothermal Titration Calorimeter 
(GE, formerly MicroCal, Piscataway, NJ). 
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b. Solution Preparation 
 The solutions of metal ions and hydroxamic acids were prepared based on mass 
measurements determined by stoichiometric calculations. The metal ions are stable in solution 
thus fresh solutions were only prepared when previously prepared solutions ran out. However, 
fresh solutions of both copper and zinc(II) were prepared to determine if the results obtained 
differed with new solutions. The same principle remained true for AHA. However, since the 
solution stability of AHA is lower than the metal ions the fresh AHA solutions were prepared for 
one run for each system within 25 minutes of beginning the experiment. Stock solutions were 
diluted following the M1V1= M2V2 to prepared the necessary concentrations for each experiment.  
c. Experimental Procedure 
 Prior to titration, the samples were usually degassed for 5 minutes to remove air bubbles 
that otherwise can get dislodged during the experiment, generating unwanted heat. When 
methanol or methanol: buffer mixture was used, samples were not degassed to avoid changes in 
solvent composition and solute concentration. A 250-µL injection syringe was filled with the 
titrant and the 1.4 mL reaction cell was filled with titrate. The reference cell was filled with 
buffer or solvent depending on the experiment. A typical experiment involved 28 injections of 
titrant of 10 µL each into the reaction cell. Each injection lasted 20 seconds and injections were 
spaced 250 or 300 seconds apart. The syringe was rotated at 307 rpm and the cell temperature 
was calibrated to 25°C.  
  For most ITC experiments, the transition metal solutions of either zinc(II) or cobalt(II) 
were loaded into the sample cell and SAHA or AHA was loaded into the syringe and inserted 
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into the sample cell. Concentrations of titrant and titrate for the different experiments varied 
(Table 1) while the basic experimental parameters of number of injections, injection volume, 
injection duration, and spacing remained the same through the experiments. Control titrations 
were performed by titrating titrant into solvent or buffer or titrating solvent or buffer into titrate. 
The heat data from these control titrations were later subtracted to remove heat effects due to 
processes other than titrant-titrate interaction. All titrations were repeated in triplicate to ensure 
that the results were reproducible.  
Table 4.1: Concentrations of Titrant and Titrate.  
Solvent Compound Titrant (mM) Compound Titrate (mM) 
Methanol: Buffer 
 
SAHA 10 
20 
Zn
2+ 
Co
2+ 
1 
3 
AHA 20 
20 
Zn
2+ 
Co
2+
 
2 
2 
Buffer AHA 50 
50 
100 
Zn
2+
 
Co
2+ 
Zn
2+ 
5 
5 
10 
Co
2+ 
50 AHA 5 
 
The 60:40 mixture is 60% anhydrous methanol and 40% buffer (50 mM NEM, 150 mM NaCl buffer pH 6.80). The 
final pH of the mixture was 6.80. The buffer is 50 mM NEM, 150 mM NaCl buffer pH 6.80. 
 
d. Data Analysis Procedures  
 Analysis of calorimetric data was carried out using the Origin 7.0 software. Data were fit 
to a one set of sites binding model using a nonlinear least square approach (Levenberg-
Marquardt algorithm). This program package uses the heats generated for each injection and 
integrates the area under or above the curve to determine binding parameters including: n (the 
number titrant of binding sites on the titrate), Ka (the equilibrium binding constant), ΔH (the 
enthalpy change per mole of titrant), and ΔS (entropy change per mole of titrant). The ΔG° (the 
Gibb’s free energy change per mole of titrant) can be calculated using the Ka.  
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 The process of fitting experimental data to a binding model involves the following steps: 
manual correction of the baseline in the raw data plots to ensure that the baseline represents the 
data correctly, subtraction from the binding isotherm an average of control isotherms, fit the data 
to the one set of sites binding model to determine the binding parameters and view the fit to 
determine if it fits the curve well. We often find it necessary to subtract an additional constant 
equaling the plateau heat of the isotherm to minimize the value for Chi-squared. This likely 
reflects the fact that the control titration isn’t a perfect control for the real control heat resulting 
from the processes other than binding, such as dilution of the titrant and titrate upon titration.  
The fitting parameters obtained after these manipulations were taken as the final binding 
parameters for each experiment. This process was repeated for each titration experiment and the 
parameters obtained were averaged and a standard deviation was calculated for each system.  
4.2  HDAC8 Fluorogenic Assays 
a. General Considerations 
Stock solution in dimethyl sulfoxide of each nitric oxide donor were prepared at 50 mM , 500 
µM and 50 µM using stoichiometric calculations to determine the mass required of each 
component. All solutions were prepared using the reagents purchased from Sigma Aldrich at the 
highest purity available. The nitric oxide donors sodium nitrite, ≥ 98.0%, sodium nitroprusside 
dehydrate, ≥ 98.0%, JS-K, ≥ 97%, Diethylamine NONOate sodium salt hydrate, S-nitroso-N-
acetyl-DL-penicillamine, ≥ 97.0%, Diethylenetriamine/nitric oxide adduct, ≥ 97.0% and L-
Cysteine, ≥ 97% were used as received. All NO donor solutions were prepared in DMSO (Sigma 
Aldrich, ≥ 99.6%) and then diluted except DETA NONOate which was prepared in MilliQ water 
with a purity of ≤ 18 MΩ. The Fluor de Lys HDAC8 substrate and developer were purchased 
from Enzo Life Sciences and were used as received. The HDAC8 assay buffer was prepared 
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using reagents from Sigma Aldrich. The assay buffer was composed of 50 mM Trizma base( ≥ 
99.9%), 137 mM NaCl ( ≥ 99.0%), 2.7 mM KCl, (≥ 99.0%) and 1 mM MgCl2 (≥ 98.0%). The pH 
of the buffer was corrected to 8.0 using a Fischer Scientific Accumet Basic AB15 pH meter. The 
pH meter was calibrated using buffer solutions at pH 4.00±0.01, 7.00±0.01, and 10.00±0.02 
purchased from Fischer Scientific. All small volume pipetting for the assays were carried out 
using Eppendorf pipettmen. Stock solutions were prepared in 1.5 mL and 0.5 mL 
microcentrifuge tubes. Solutions were mixed using the Fischer Scientific Vortex Mixer. The 
microtitrate plate was read on the LBioTech Synergy H1 Hybrid Reader visualized using the 
Gen5 2.00 software . All data obtained was analyzed using Microsoft Excel 2007. All enzyme 
assays were performed in triplicate in 96 well plate format and the average values were used for 
analysis.  
b. Assay Procedures  
To begin, 15 µL HDAC8 enzyme (≥ 90.0% Sigma Aldrich) at 400 nM (some assays using 
100 or 25 nM) was incubated for 30 minutes with 10 µL the required concentration of nitric 
oxide donor. Additionally, a DMSO control containing no nitric oxide donor was performed for 
each assay. After the incubation, 25 µL of 50 µM Fluor de Lys substrate was added and allowed 
to react for 30 minutes. Finally, 50 µL of 1X Fluor de Lys Developer was added and incubated 
for 1 hour. After the incubation, the microtitrate plate was read at 360 and 480 nm (the optimum 
wavelengths for coumarin fluorescence)  
c. 4-Amino-7-methylcoumarin (AMC) Standard Curve  
A standard curve plotted using the concentration of AMC versus the relative fluorescence 
units was constructed. The volume of DMSO did not exceed 10% of the 50 µL total reaction 
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volume. Using a 100 mM stock of AMC in DMSO, serial dilutions of 10 mM, 1 mM and 0.1 
mM were prepared. Concentrations of AMC between 500 nM and 100 µM were prepared in the 
wells using the AMC stocks, DMSO and assay buffer as shown in Table 4.1.  The plate was read 
at 380 and 460 nm.  
Table 4.2: Sample Components for AMC Standard Curve. 
[AMC] Volume AMC (µL) Volume DMSO (µL) Volume Buffer (µL) 
0 0 5 45 
500 nM 2.5 of 10 µM 2.5 45 
1 µM 0.5 of 100 µM 4.5 45 
10 µM 0.5 of 1 mM 4.5 45 
25 µM 1.25 of 1 mM 3.75 45 
50 µM 2.5 of 1 mM 2.5 45 
100 µM 0.5 of 10 mM 4.5 45 
 
d. Preparation of  S-nitrosocysteine  
In a microfuge tube, 0.05 mmol L-cysteine was dissolved in 1.0 mL of 0.5 N HCl. Once 
dissolved, 0.5 mmol sodium nitrite was also dissolved in the solution. The pH of solution was 
adjusted to neutral using 1.0 M NaOH. Once prepared, the stock solution was diluted to 500 µM 
and 50 µM in DMSO.  
e. Preparation of  Ethanesulfohydroxamic acid  
Ethanesulfohydroxamic acid was prepared in the Karver lab according to literature 
procedures. 
32
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